Transgene releases investor presentation on individualized neoantigen cancer vaccine platform in early-stage tumors

  • Transgene highlighted its myvac individualized neoantigen cancer vaccine platform, targeting relapse prevention in early-stage solid tumors.
  • Lead program TG4050 in resected head and neck cancer showed 100% 2-year DFS in treated patients in the Phase 1 part.
  • Randomized Phase 2 TG4050 readout set for end of Q1 2028, focused on 2-year DFS; first immunogenicity data expected in H2 2026.
  • Second candidate TG4070 entered a randomized Phase 1 in resected NSCLC with nivolumab; safety is the primary endpoint, 18-month EFS a key secondary.
  • Company disclosed a market cap of about EUR 220 million, 160 employees, funding runway into early 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transgene SA published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.